Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Total payments for the HIV prevention pill exceeded $2 billion in 2018.
Rates also declined among Black and Latino men, though COVID-19 disruptions threaten the trend.
This finding calls into question research that has projected that frequent testing among men on PrEP could drive down STI rates.
The D-peptide HIV entry inhibitor CPT31 is being developed with hopes it could be injected quarterly for both treatment and prevention.
A digital dashboard displays six gauges in the nation’s effort to lower HIV rates by 90% by 2030.
At My House Clinic, which also offers hep C and COVID-19 services, PRIDE stands for “Promotes Respect Inclusion & Dignity for Everyone.”
Virtual discussions in Texas and Los Angeles shed light on “the dark side of the rainbow.”
Here’s how the nation’s capital remains on track despite COVID-19.
A study found that men who started PrEP a week before a vacation and stopped a week after coming home adhered well to the daily regimen.
A low-cost generic version of Truvada as PrEP will hit the market September 30.
The 2-1-1 HIV prevention regimen offers an option for those who don’t want to take daily pills.
Cabotegravir injections given every eight weeks as PrEP are even more effective than daily Truvada.
Bob the Drag Queen hosts an educational entertainment event to tackle HIV issues.
Researchers ran a Gallup poll of HIV-negative transgender people to assess their risk of HIV, familiarity with PrEP and other factors.
This is according to nationally representative survey data of gay and bi men diagnosed with the virus.
Whether the donor uses antiretrovirals for HIV treatment or as PrEP, the drugs could mask the presence of the virus in a blood donation.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.